Company intelligence / Profile preview

En Carta Diagnostics

Paris, Île-de-France, Franceencarta.bio ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

The company has developed five prototypes and published ten scientific papers demonstrating proof of concept for rapid molecular detection of various pathogens. Its lead product—a point-of-care diagnostic kit for early Lyme disease detection—aims to provide PCR-level accuracy without specialized equipment or medical professionals. Preclinical data on the Lyme test are expected in early 2025. The technology has also secured a commercial contract with a digital healthcare leader and received significant DARPA funding for related research.

Therapeutic areas: Infectious Diseases
Modalities: AptamerMolecular diagnostics platform (synthetic biology-based)
Industry: Molecular Diagnostics

Partnerships

Digital healthcare leader (undisclosed commercial contract partner)

Beyond the preview

Go deeper on En Carta Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on En Carta Diagnostics.

Explore the full profile